June 14, 2011
Biomoda, Inc. (OTCBB: BMOD) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.
According to John Cousins, President of Biomoda, “Our pilot clinical study demonstrated the CyPath® assay’s utility as a cancer diagnostic. We expect the unique properties of the CyPath® labeling solution that allow it to bind to cancer cells and cause them to fluoresce can also play a significant role in determining the efficacy of cancer treatment. Doctors will be able to take fluid or tissue samples at intervals during chemotherapy, treat them with the CyPath® solution and compare the results to the baseline assay to see if the percentage of cancerous and abnormal cells is moving in the right direction.”
May 17, 2011
Biomoda (OTCBB: BMOD) has announced significant additions to its Intellectual Property (IP) portfolio, including a Canadian patent for using its proprietary porphyrin-based compound to detect cancer and trademark protection for Biomoda’s CyPath® assay kits and reagents in the European Union.
According to John Cousins, President of Biomoda, “While we work toward FDA approval and commercialization of our CyPath® diagnostic for lung cancer, it is critically important to make sure that our technology and the IP behind it are protected. Cancer is a global health crisis with the number of diagnoses and deaths expected to double by 2030. We will continue to expand the geographic reach of our IP protection in order to make the CyPath® assay available worldwide.”
April 5, 2011
Biomoda (OTCBB: BMOD) released top line results of the Company’s pilot clinical trials for its CyPath diagnostic for lung cancer. The results were statistically significant and the Company’s CEO, Maria Zannes, was a featured interview on several nationally syndicated business talk radio shows. These interviews are archived on the Biomoda’s website, www.biomoda.com.
April 4, 2011
LifeTech Capital has updated its independent research coverage on Biomoda (OTCBB: BMOD) based on top-line results of the pilot clinical trial of Biomoda’s CyPath® diagnostic assay for lung cancer.
LifeTech recommends Biomoda as a “Strong Speculative Buy” stating the company’s pilot trial demonstrates proof of concept, provides “best results yet for lung cancer screening” and does not expose patients to ionizing radiation. The report was written by Stephen M. Dunn, Senior Managing Director, Research, and William D. Dawson, Senior Vice President, Research, for LifeTech Capital, a division of Aurora Capital LLC, and is available online at www.lifetechcapital.com/reports.htm.
March 31, 2011
Biomoda (OTCBB: BMOD) has entered into a Memorandum of Understanding with the University of Texas Health Science Center at San Antonio to collaborate on research to optimize the CyPath® diagnostic assay for lung cancer.
According to John Cousins, President of Biomoda, “Our research will progress more quickly and our science will be strengthened by this initiative. Biomoda is focused on optimization of its assay to include automating sample reading through flow cytometry and refining the use of fluorescent microscopy to identify cancer cell types and pre-cancerous cells. The Health Science Center not only will greatly assist us with the science, but we believe the partnership has the potential to create jobs and economic growth for the region.”
March 30, 2011
Biomoda (OTCBB: BMOD) released top line results for its pilot study for lung cancer and we are pleased with what we saw. In short, the study provides evidence to conclude that the Company’s biomarker assay, CyPath, can discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.
The key to cancer survival, whether it is lung cancer or any other form of cancer, is early detection. And based on results from this study, Biomoda is able to identify and quantify cellular characteristics that differ between groups of individuals at high risk for developing cancer and those who already have the disease. At this point, this is exactly what the Company was hoping for. Going forward there are certain areas which can be improved, but that is really just tweaking that which we know works.
Congrats to the Biomoda team for a job well done. We look forward to continued success from the Company.
March 15, 2011
Biomoda (OTCBB: BMOD), having completed enrollment for its pilot clinical study, seeks to optimize its assay and to automate the process for reading CyPath®-labeled cells. In so doing, the Company will benefit from lower costs and greater accuracy in a high-throughput clinical setting. In addition, Biomoda’s ongoing research, both independently and in partnership with other scientific and medical institutions, is focused on improving methods for the non-invasive collection of sputum samples and refining the use of fluorescent microscopy to identify cancer and pre-cancerous cells.